Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma2019 · 3,752 citations
2. 2Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.2024 · 12 citations
3. 3Dual Checkpoint Inhibition in Melanoma With ≥1% PD-L1—Time to Reassess the Evidence2024 · 12 citations
4. 4Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma2024 · 506 citations
5. 5Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater2019 · 1,734 citations